Coya Therapeutics (NASDAQ:COYA) Given "Buy" Rating at Chardan Capital

Key Points

• Chardan Capital has reaffirmed a "buy" rating for Coya Therapeutics (NASDAQ:COYA) with a target price of $14.00, suggesting a potential upside of 132.17% from its current trading price.
• Analysts are mixed on COYA, with four maintaining "buy" ratings and one putting a "sell" rating, resulting in a consensus rating of "Moderate Buy" and a target price of $16.50.
• Coya Therapeutics reported a quarterly loss of ($0.36) EPS, significantly missing expectations, and its stock has seen a market capitalization of around $100.88 million as trading volumes remain low.

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research note published on Wednesday,Benzinga reports. Chardan Capital currently has a $14.00 price target on the stock.

Several other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. D. Boral Capital restated a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Thursday, July 24th. Lake Street Capital began coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, June 9th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Coya Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Coya Therapeutics Stock Performance

Coya Therapeutics stock traded up $0.47 during midday trading on Wednesday, reaching $6.15. 23,608 shares of the company's stock were exchanged, compared to its average volume of 62,990. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24. The firm has a market cap of $102.89 million, a price-to-earnings ratio of -4.96 and a beta of 0.26. The stock's 50-day simple moving average is $5.97 and its 200 day simple moving average is $6.08.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The company had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.78 million. Research analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in COYA. DME Capital Management LP raised its position in shares of Coya Therapeutics by 29.2% in the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after buying an additional 372,414 shares in the last quarter. Dauntless Investment Group LLC acquired a new position in Coya Therapeutics during the first quarter valued at approximately $1,083,000. CM Management LLC raised its position in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after purchasing an additional 40,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics during the second quarter valued at approximately $119,000. Finally, Jane Street Group LLC raised its position in Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after purchasing an additional 13,176 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.